未登录

W

Wei Cong

Southwest Medical University

H指数:20

被引数:1,103

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biochanin A Attenuates Renal Fibrosis Via Selective Inhibition of Smad3-mediated Epithelial-Mesenchymal Transition in a Murine Unilateral Ureteral Obstruction Model

Biochanin A 通过选择性抑制 Smad3 介导的上皮-间质转化，减轻小鼠单侧输尿管梗阻模型中的肾纤维化。

Cell Biology International

IF3.1

2025-10-280

PRE

A novel angiotensin-converting enzyme (ACE) inhibitory peptide from Alaska pollock (Gadus chalcogrammus) Skin: Preparation, screening, in vitro activity evaluation, and network pharmacology analysis

一种来自阿拉斯加狭鳕（Gadus chalcogrammus）鱼皮的血管紧张素转换酶（ACE）抑制肽：制备、筛选、体外活性评价和网络药理学分析

Food Bioscience

IF5.9

2025-10-210

PRE

Crystal structure of (3-(dimethoxymethyl)-5-methoxy-1H-indol-1-yl) (2-iodo-5-methoxyphenyl)methanone, C20H20INO5

(3-(二甲氧基甲基)-5-甲氧基-1H-吲哚-1-基)(2-碘-5-甲氧基苯基)甲酮的晶体结构，C20H20INO5

ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES

IF0

2025-09-010

OA

Development and external validation of a predictive model for lung metastases in kidney cancer based on clinical and laboratory features

基于临床和实验室特征开发并外部验证一种用于肾癌肺转移的预测模型

Clinical and Experimental Medicine

IF3.5

2025-08-140

OAAI

Photodynamic/photothermal pH-responsive mannose-based dimeric prodrug for synergistic overcoming the biological barriers to conquer multidrug resistance in MRSA

MATERIALS & DESIGN

IF7.9

2024-08-010

OAAI

Mechanism of Chaihuang-Yishen formula to attenuate renal fibrosis in the treatment of chronic kidney disease: Insights from network pharmacology and experimental validation

柴黄益肾方治疗慢性肾脏病减轻肾纤维化的作用机制: 网络药理学及实验验证

IF3.6

2024-08-010

OAAI

Shensong yangxin, a multi-functional traditional Chinese medicine for arrhythmia: A review of components, pharmacological mechanisms, and clinical applications

IF3.6

2024-08-012

OAAI

Tongxinluo capsule as a multi-functional traditional Chinese medicine in treating cardiovascular disease: A review of components, pharmacological mechanisms, and clinical applications

通心络胶囊作为治疗心血管疾病的多功能中药: 成分，药理机制和临床应用综述

IF3.6

2024-07-012

OAAI

Diet-Induced Upregulation of LRG1 Contributes to Renal Lipotoxicity and Damage in Chronic Kidney Disease

IF7.5

2024-06-140

PRE

Mechanism of Bazi Bushen capsule in delaying the senescence of mesenchymal stem cells based on network pharmacology and experimental validation

IF3.6

2024-03-012

OAAI

Qili Qiangxin (QLQX) capsule as a multi-functional traditional Chinese medicine in treating chronic heart failure (CHF): A review of ingredients, molecular, cellular, and pharmacological mechanisms

IF3.6

2023-11-019

OAAI

Maximum intensity projection based on high frame rate contrast-enhanced ultrasound for the differentiation of breast tumors

基于高帧率超声造影的最大强度投影鉴别乳腺肿瘤

FRONTIERS IN ONCOLOGY

IF3.3

2023-10-303

OAAI

Repositioning of clinically approved drug Bazi Bushen capsule for treatment of Aizheimer's disease using network pharmacology approach and in vitro experimental validation

IF3.6

2023-07-015

OAAI

Embryonic thermal manipulation leads growth inhibition and reduced hepatic insulin-like growth factor1 expression due to promoter DNA hypermethylation in broilers

POULTRY SCIENCE

IF4.2

2023-04-017

OAAI

Constant light in early life induces fear-related behavior in chickens with suppressed melatonin secretion and disrupted hippocampal expression of clock- and BDNF-associated genes

JOURNAL OF ANIMAL SCIENCE AND BIOTECHNOLOGY

IF6.5

2022-06-2111

OA

Valeriaquinone A, a unique anthraquinone-coumarin hybrid with selective inhibition of PTP1B from Knoxia valerianoides

CHINESE CHEMICAL LETTERS

IF8.9

2022-06-018

PRE

Chronic corticosterone disrupts the circadian rhythm of CRH expression and m6A RNA methylation in the chicken hypothalamus

JOURNAL OF ANIMAL SCIENCE AND BIOTECHNOLOGY

IF6.5

2022-03-0811

OA

Trifluoromethyl-substituted 3,5-bis(arylidene)-4-piperidones as potential anti-hepatoma and anti-inflammation agents by inhibiting NF-κB activation

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

IF5.4

2021-07-207

OAAI

Dissymmetric pyridyl-substituted 3,5-bis(arylidene)-4-piperidones as anti-hepatoma agents by inhibiting NF-κB pathway activation

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2019-04-0144

PREAI

N-phenylsulfony1-3,5-bis(arylidene)-4-piperidone derivatives as activation NF-κB inhibitors in hepatic carcinoma cell lines

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2018-07-0146

PREAI